Results 101 to 110 of about 6,337 (198)

In Vitro Screening of Anti-Viral and Virucidal Effects Against SARS-CoV-2 by Phenylamino-Phenoxy-Quinoline Derivatives: An Integrative Computational Approach [PDF]

This study investigated the binding interactions between three groups of 2,4-disubstituted phenylamino-phenoxyquinoline derivatives 1-3(a-d) and four readily available drugs (ritonavir, ensitrelvir, nirmatrelvir, and paxlovid) with severe acute ...
Baicharoen, Apisara, Jittmittraphap, Akanitt, Jityuti, Benchawan, Kuno, Mayuso, Leaungwutiwong, Pornsawan, Makarasen, Arthit, Ngueanngam, Natchaphon, Patnin, Suwicha, Techasakul, Supanna, Vijitphan, Pongsit   +9 more
core   +1 more source

COVID-19 Biopharmaceutical Innovation and Industry Appropriation [PDF]

The rapid emergence of vaccines and therapeutics in response to the onset of the coronavirus (COVID-19) pandemic demonstrated the value of medical innovation. These advances not only led to enhanced patient welfare by reducing the disease’s mortality and
Abbasi, Attaullah, Di Cera, Giuseppe, Fendrick, A. Mark, Guo, Susu, Kataria, Aarushi, Philipson, Tomas J., Zhao, Qi   +6 more
core   +1 more source

Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China

Infection and Drug Resistance
Wei Yang,1,* Yahui Peng,1,* Changsong Wang,1,* Hongliu Cai,2 Lina Zhang,3 Jun Xu,2 Yongjie Wang,4 Maonan Wang,4 Mingyan Zhao,1 Kaijiang Yu1 1Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University ...
Yang W, Peng Y, Wang C, Cai H, Zhang L, Xu J, Wang Y, Wang M, Zhao M, Yu K   +9 more
doaj  

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +1 more source

Computational molecular modeling of Paxlovid binding

, 2022
Computational binding modeling of the drug Paxlovid to the 3CL-protease of SARS-Cov-2 is presented. Paxlovid contains 2 molecule ingredients: Nirmatrelvir and Ritonavir. This is a detailed distributional analysis using docking of both small molecules, to the target protease and to the CYP 3A4 liver enzyme.
openaire   +1 more source

Yi-Qing Oral Solution and Paxlovid combination for COVID-19: Efficacy and safety in a randomized controlled trial

Traditional Medicine and Modern Medicine
Background: The COVID-19 pandemic has exerted a significant social burden worldwide. Traditional Chinese medicine has emerged as a vital role in the clinical management of COVID-19.
Maimaititusun Yalikun, Xi Huang, Xueyi Zhu, Yuxue Cao, Jiming Zhang, Xin Ma, Jindong Hua, Jiaqi Liu, Xianjun Sun, Wenjing Du, Lingwen Kong, YanBo Ren, Hongli Xue, Baojun Liu, Yuanhao Zhang, Yang Lei, Zhen Gao, Weiyi Gong, Jingcheng Dong   +18 more
doaj   +1 more source

Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients

Scientific Reports
This retrospective cross-sectional study aims to evaluate the safety, tolerability, and adherence of patients prescribed Nirmatrelvir-ritonavir (Paxlovid) in outpatient settings, focusing on its use in managing category 2 COVID-19 patients across three ...
Zahirah Zaharuddin, Nur Sabiha Md Hussin, Mahmathi Karuppannan   +2 more
doaj   +1 more source

The path to Paxlovid

C&EN Global Enterprise, 2022
openaire   +2 more sources

Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19. A prospective study [PDF]

COVID-19 represents a threat for frailty patients. This study compares molnupiravir and nirmatrelvir for fragile COVID19 patients' efficacy, safety, and cost.
Cattaruzza, Maria Sofia, Cipriano, Enrica, Lordi, Margherita, Pietrantonio, Filomena, Rosiello, Francesco, Ruggeri, Matteo, Vinci, Antonio   +6 more
core   +1 more source

A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

eLife
Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients.
Zhanwei Du, Lin Wang, Yuan Bai, Yunhu Liu, Eric HY Lau, Alison P Galvani, Robert M Krug, Benjamin John Cowling, Lauren A Meyers   +8 more
doaj   +1 more source